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Abstract
Background: The membrane transporters such as P-glycoprotein (Pgp), the MDR1 gene product, are one
of causes of treatment failure in cancer patients. In this study, the epigenetic mechanisms involved in
differential MDR1 mRNA expression were compared between 10 gastric and 9 colon cancer cell lines.
Methods: The MDR1 mRNA levels were determined using PCR and real-time PCR assays after reverse
transcription. Cytotoxicity was performed using the MTT assay. Methylation status was explored by
quantification PCR-based methylation and bisulfite DNA sequencing analyses.
Results: The MDR1 mRNA levels obtained by 35 cycles of RT-PCR in gastric cancer cells were just
comparable to those obtained by 22 cycles of RT-PCR in colon cancer cells. Real-time RT-PCR analysis
revealed that MDR1 mRNA was not detected in the 10 gastric cancer cell lines but variable MDR1 mRNA
levels in 7 of 9 colon cancer cell lines except the SNU-C5 and HT-29 cells. MTT assay showed that Pgp
inhibitors such as cyclosporine A, verapamil and PSC833 sensitized Colo320HSR (colon, highest MDR1
expression) but not SNU-668 (gastric, highest) and SNU-C5 (gastric, no expression) to paclitaxel.
Quantification PCR-based methylation analysis revealed that 90% of gastric cancer cells, and 33% of colon
cancer cells were methylated, which were completely matched with the results obtained by bisulfite DNA
sequencing analysis. 5-aza-2'-deoxcytidine (5AC, a DNA methyltransferase inhibitor) increased the MDR1
mRNA levels in 60% of gastric cells, and in 11% of colon cancer cells. Trichostatin A (TSA, histone
deacetylase inhibitor) increased the MDR1 mRNA levels in 70% of gastric cancer cells and 55% of colon
cancer cells. The combined treatment of 5AC with TSA increased the MDR1 mRNA levels additively in
20% of gastric cancer cells, but synergistically in 40% of gastric and 11% of colon cancer cells.
Conclusion: These results indicate that the MDR1 mRNA levels in gastric cancer cells are significantly
lower than those in colon cancer cells, which is at least in part due to different epigenetic regulations such
as DNA methylation and/or histone deacetylation. These results can provide a better understanding of the
efficacy of combined chemotherapy as well as their oral bioavailability.
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Background
Gastric and colorectal cancers are a cause of morbidity and
mortality in the world today. If a curative surgical resec-
tion is impossible, these cancers respond very poorly to
chemotherapy and resulting in a poor prognosis. In gas-
tric cancer patients, 5-fluorouracil (5-FU) based combina-
tion chemotherapy have been attempted in order to
improve the treatment outcomes [1]. With colorectal can-
cer, 5-FU has been the most widely used drug for more
than 40 years. However, other agents such as irinotecan or
oxaliplatin have been used to improve the antitumor effi-
cacy in combination with 5-FU [2]. 5-FU interferes with
DNA synthesis by blocking the production of pyrimidine
nucleotide dTMP from dUMP during de novo DNA synthe-
sis through the inhibition of thymidylate synthase as well
as through the incorporation of fluoro-nucleotides into
the DNA and RNA [3].
P-glycoprotein (Pgp) encoded by the multidrug resistance
1 (MDR1) gene is a representative membrane efflux pump
of ATP-binding cassette (ABC) transporters [4-6]. Pgp
functions as energy-dependent efflux pumps of a variety
of structurally diverse chemotherapeutic agents such as
doxorubicin, vincristine, vinblastine, paclitaxel, colhicine,
actinomycin D and mitomycin C [7], which can decrease
the intracellular level of drug accumulation. As a result,
overexpression of these proteins confers MDR to cancer
cells by evading the cytotoxic effects of drugs. In the
human intestine, Pgp is strongly expressed on the apical
surface of the superficial columnar epithelial cells of the
ileum and colon, and its expression level decreases gradu-
ally proximally into the jejunum, duodenum and stom-
ach [8]. Regulation of the transcriptional activity of the
MDR1 gene is dependent on several trans-acting proteins
that bind the consensus cis-elements [9]. The accessibility
of the promoter elements to their binding factors is regu-
lated at the level of chromatin assembly. The levels of
both DNA methylation and histone deacetylation regu-
late MDR1 gene expression [10-12]. So far, the transcrip-
tional regulation of MDR1  gene expression through
epigenetic mechanisms has been reported in expression in
colon cancer cells [13-16] but none in gastric cancers cells.
Furthermore, the relationships between the transcrip-
tional expression of MDR1 gene expression and epigenetic
mechanisms in gastric and colon cancer cells have not
been compared. Therefore, it is unclear why chemother-
apy regimens have been differently used to treat gastric
and colorectal cancers and why MDR1 mRNA is expressed
differentially in gastric and colorectal cancer cells. There-
fore, this study examined whether or not the degree of
methylation at the promoter site of the MDR1 gene is
closely associated with MDR1 gene expression in both
cancer cells.
Methods
Cell culture
The 10 human gastric cancer cell lines (SNU-1, -5, -16, -
216, -484, -601, -620, -638, -668 and -719) and 9 colon
cancer cell lines (SNU-C1, -C4, -C5, Colo320HSR, LoVo,
DLD-1, HT-29, HCT-8 and HCT-116) were obtained from
the Cancer Research Center at Seoul National University
(South Korea). All the cells were cultured at 37°C in a 5%
CO2 atmosphere using RPMI 1640 medium (GibcoBRL,
Gland Island, NY, USA) with 10% heat inactivated fetal
bovine serum (Sigma, ST. Louis, MO, USA). The cells were
maintained either as a suspension or a monolayer culture,
and subcultured until they reached confluence.
Reverse transcription-polymerase chain reaction (RT-
PCR) assay
The total RNA was extracted using MagExtractor® for the
MFX-2100 (Toyobo, Osaka, Japan) auto-nucleic acid puri-
fication system, according to the manufacturer's instruc-
tions. The MDR1  and  β-actin  mRNA transcripts were
detected using the RT-PCR assay. MDR1 expression was
detected with the 5' and 3' primers corresponding to the
nucleotides 907–930 (5'-CTGGTTTGATGTGCACGAT-
GTTGG-3') and 1179–1201 (5'-TGCCAAG-ACCTCT-
TCAGCTACTG-3'), respectively, of the published cDNA
sequence [17], yielding a 296-bp PCR product. β-actin
mRNA expression was used as a control for the amount of
RNA, and was detected with the 5' and 3' primers corre-
sponding to nucleotides 1912–1932 (5'-GACTATGACT-
TAGTTGCGTTA-3') and 2392–2412 (5'-
GTTGAACTCTCTACATACTTCCG-3'), respectively, of the
published cDNA sequence [18], yielding a 501-bp PCR
product. The RNA from each sample was reverse tran-
scribed using 200 units of Moloney murine leukemia
virus reverse transcriptase (Gibco-Bethesta Research Labo-
ratory, Grand Island, NY, USA) and 0.18 μg/ml oligo
(dT20) primer for 1 hr at 37°C. The resulting cDNA of the
gastric cancer cells (2-fold diluted cDNA in the colon can-
cer cells) were amplified with 1.25 units of Taq polymer-
ase (PE Applied Biosystems, Foster City, CA, USA), 1 mM
MgCl2 and 10 pmole of each primer in a thermal cycler
(GeneAmp 2400, PE Applied Biosystems, Boston, MA,
USA) for 22 cycles with the colon cancer cells but 35 cycles
with the gastric cancer cells for MDR1 and 17 cycles for β-
actin  of the sequential denaturation (94°C for 30 s),
annealing (65°C for MDR1, 53°C for β-actin), and exten-
sion (72°C for 30 s). After the final cycle, all the PCR
products were subjected to a final extension of 5 min at
72°C. For quantitation, 3 μCi of [α-32P] dCTP were added
to each reaction mixture. After PCR, the PCR products
were combined and then electrophoresed on a 7.5% non-
denaturing polyacrylamide gel. The bands were scanned
with a densitometer (Pdi, Huntington Station, NY, USA).
The amount of each mRNA transcript was normalized
with that of each β-actin mRNA.BMC Gastroenterology 2008, 8:33 http://www.biomedcentral.com/1471-230X/8/33
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Protein extraction and Western blot analysis
Total cell lysates were prepared by lysing harvested cells in
extraction buffer (1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS in phosphate-buffered saline) supplemented
with 2 mM phenylmethylsulfonyl fluoride (Sigma) and
10 μg/ml leupeptin (Sigma). DNA was sheared by sonica-
tion and Western blotting analysis was performed using a
slight modification of the method first described by Tow-
bin et al. [19]. Proteins were transferred onto a nitrocellu-
lose membrane by electroblotting using a current of 60 V
overnight. The membrane was incubated in blocking
solution (5% skim milk) for 1 hr at room temperature,
washed, and then incubated with primary goat polyclonal
antibody (1:1000, Santa Cruz, Biotechnology, CA, USA)
for Pgp. The membrane was washed and incubated with
horseradish peroxidase-conjugated secondary antibody
(diluted 1:1000) against each IgG for hosts of primary
antibodies for 1 hr. The membrane was then stained using
the detection reagent of the ECL detection kit (Amersham,
Piscataway, NJ, USA).
Real-time PCR
Extraction of mRNA was performed according to the RNe-
asy proctocol (Qiagen, Hilden, Germany). One micro-
gram of total RNA was reversely transcribed into cDNA in
a volume of 20 μl with 200 units of Moloney murine
leukemia virus reverse transcriptase (Gibco-Bethesta
Research Laboratory, Grand Island, NY, USA) and 0.18
μg/ml oligo (dT20) primers (Promega, Madison, USA)
according to the manufacture's manual. Real-time PCR
was performed with the Light Cycler 2.0 Instrument
(Roche, Mannheim, Germany) using the Fast Start DNA
Master SYBR Green I Kit (Roche). For verification of the
correct amplification product, PCRs were analyzed on a
2% agarose gel stained with ethidium bromide. The
sequences of the primers are as follows: for β-actin, 5'-
GACTATGACTTAGTTGCGTTA-3' and 5'-GTTGAACTCTC-
TACATACTTCCG-3'; for MDR1, 5'-CTGGTTTGATGT-
GCACGATGTTGG-3' and 5'-
TGCCAAGACCTCTTCAGCTACTG-3'. Each reaction (20
μl) contained 4 μl cDNA (10-fold dilution), 4 mM MgCl2,
10 pmole of each primer and 2 μl of Fast Start DNA Master
SYGR Green I Mix containing buffer, dNTPs, SYBR Green
dye and Tag polymerase. The amplification procedure of
target genes was as follows: pre-denaturing at 95°C for 10
min, 40 cycles of denaturing at 95°C for 15 sec, annealing
for MDR1 at 67°C (β-actin at 55°C) for 5 sec, and exten-
sion at 72°C for 7 sec (β-actin for 21 sec). Melting curve
analysis was performed to confirm production of a single
product. Negative controls without template were pro-
duced for each run. Gene expression values (relative
mRNA levels) are expressed as ratios (difference between
the Ct values = The point on the curve in which the
amount of fluorescence begins to increase rapidly, usually
a few standard deviations above the baseline, is termed
the threshold cycle (Ct value).) between the gene of inter-
est (MDR1 mRNA) and an internal reference gene (β-actin
mRNA) that provide a normalization factor for the
amount of RNA isolated from a specimen. Analysis of data
was performed using Light Cycler software version 4.0
(Roche).
Cytotoxicity test using MTT assay
The in vitro cytotoxicity of the drugs was measured using
an MTT assay, as described elsewhere [20]. The cells were
seeded at a 2 × 104cells/ml and incubated overnight to
allow for attachment and stabilization. The cells were
incubated at 37°C for 3 days, and MTT [3-(4,5-dimethyl-
thiazole-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma]
solution was then added to each well containing the cells.
After shaking for 1 min, the plate was incubated for 5 hr.
Formazan crystals of the suspension culture were dis-
solved in 150 μl of dimethylsulfoxide (DMSO) after
removing the supernatant. The optical density of the wells
was measured with a microplate reader (μQuant, Bio-tek
Instruments Inc., Winooski, VT, USA) at 540 nm.
Quantification PCR-based methylation analysis
Five micrograms of the genomic DNA was digested with
50 U of Msp I or Hpa II (Fermentas MBI, Vilnius, Lithua-
nia) at 37°C for 16 hours, added to a 1/15 volume of 0.6
M Tris (pH 7.5) and 1.5 M NaCl, and digested with 50 U
of Pst I (New England Biolabs, MA, USA) at 37°C for 8
hours. The methylation status of the MDR1 5'CpG pro-
moter region was examined by analyzing 100 ng restric-
tion-digested DNA by PCR in 25 μL reactions containing
1.25 units of Taq DNA polymerase and 10 pmole of each
primer. The quantification PCR-based methylation analy-
sis was carried out according to the method reported pre-
viously [11]. The PCR primers used were 5'-
TCTAGAGAGGTGCAACGGAAG-3' and 5'-TCAGCCT-
CACCACAGATGAC-3' for the MS1 methylation-sensitive
primers (121 bp), 5'-TGAAGTCCTCTGGCAAGTCC-3'
and 5'-ATTCTCCCTCCCGGTTCC-3' for the MS2 methyl-
ation-sensitive primers (206 bp), 5'-ATTTCACGTCTT-
GGTGGCC-3' and 5'-TCCAGTGCCACTACGGTTT-G-3'for
the MC positive control primers (240 bp), and 5'-
GGCGAAGGAGGT-TGTCTATTC-3' and 5'-AACGT-
TCTAGGAGAGTCGGG-3' for MN negative control prim-
ers (240 bp) derived from the triosephosphate isomerase
gene promoter region. Amplification was performed in a
DNA thermal cycler for 35 cycles for the MN, MC, MS1
and MS2 primers involving in sequence denaturation
(95°C for 30 s), annealing (60°C for 30 s), and extension
(72°C for 30 s). After the final cycle, all the PCR products
were subjected to a final extension for 5 min at 72°C. The
PCR products were separated by electrophoresis on 7%
PAGE gels. The gels were then stained with ethidium bro-
mide, and photographed by using a Kodak Image Station
4000 MM (Eastman Kodak, Rochester, NY, USA).BMC Gastroenterology 2008, 8:33 http://www.biomedcentral.com/1471-230X/8/33
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Bisulfite DNA sequencing analysis
One μg of genomic DNA was chemically modified by
sodium bisulfite using the EZ DNA Methylation kit
(Zymo Research, Orange, CA, USA) to convert unmethyl-
ated cytosines to uracils while leaving methylated
cytosines unaltered. The bisulfite-modified DNA was used
for PCR amplification. Extended MS1 primer contains 10
CpG sites, and 2 SP-1 sites which are mandatory for the
functional  MDR1  promoter to be activated [21]. The
primer sequences for amplification of bisulfite-treated
strands (223 bp) were as follows: S: 5'-GGAAGTTA-
GAATATTTTTTTTGGAAAT-3'; AS: 5'-ACCTCTACTTCTT-
TAAACTTAAAAAAACC-3'. Amplification was performed
in the same PCR conditions except 48°C annealing tem-
perature and 45 PCR cycles. After the final cycle, all the
PCR products were subjected to a final extension at 72°C
for 5 min. Sequence of PCR products was analyzed using
an automated sequencer (Applied Biosystems, Foster City,
CA, USA).
Statistical Analysis
The results are presented as a mean ± SE and the data was
analyzed using the Student's t-test. P values < 0.05 were
considered significant.
Results
Comparison of expression profiles of MDR1 mRNA in 
gastric and colon cancer cells
MDR1 mRNA expression was analyzed using the RT-PCR
assay with the expression level being normalized with the
β-actin mRNA levels obtained after 17 cycles of PCR. The
MDR1 mRNA was not detected after 22 cycles of PCR in
the 10 gastric cancer cell lines but could be detected at var-
iable levels after 35 cycles of PCR with the exception of
SNU-16, suggesting a significantly low level of MDR1
mRNA expression in the gastric cancer cells tested (Figure
1). As shown in Figure 1, the rank order according to the
MDR1-β-actin ratio in the gastric cancer cell lines is as fol-
lows: SNU-668 (1.51) > SNU-484 (1.37) > SNU-5 (0.63)
> SNU-601 (0.33) > SNU-719 (0.32) > SNU-216 (0.29) >
SNU-638 (0.07) > SNU-1 (0.04) > SNU-16 (0). Of the 9
colon cancer cell lines, variable MDR1 mRNA levels could
be detected in 7 colon cancer cell lines after 22 cycles of
PCR but not in the SNU-C5 and HT-29 cells. The MDR1
mRNAs of the two latter cells could be not detected even
after 35 cycles of PCR. These results suggest a relatively
high level of MDR1 mRNA expression in spite of some
exceptions in the colon cancer cells. As shown in Figure 2,
the rank order according to the MDR1/β-actin ratio in the
colon cancer cell lines is as follows: Colo320HSR (0.90) >
SNU-C4 (0.45) > HCT-8 (0.26) > SNU-C1 (0.12) > HCT-
116 (0.11) > LoVo (0.10) > DLD-1 (0.07) > SNU-C5 (0) =
HT-29 (0).
We performed again the real-time RT-PCR assay for the
quantitative validation of MDR1 mRNA levels obtained
from RT-PCR assay. The MDR1 mRNA was not detected in
the 10 gastric cancer cell lines. However, of the 9 colon
cancer cell lines, variable MDR1 mRNA levels could be
detected in 7 colon cancer cell lines except the SNU-C5
and HT-29 cells as the RT-PCR data (Figure 3).
Taken together, the MDR1 mRNA levels in the gastric can-
cer cell lines were significantly lower than those in the
colon cancer cell lines.
Chemosensitizing effects of Pgp inhibitors in gastric and 
colon cancer cells
Although the protein levels were not examined in this
study, functional studies were performed using the Pgp
inhibitors in the gastric and colon cancer cell lines
expressing the highest level of MDR1 mRNA expression.
As shown in Figure 4A, the Colo320HSR cells (colon,
mutant p53, highest expression of MDR1 mRNA) were
14-fold and > 200 times resistant to paclitaxel than the
SNU-C5 and SNU-668 cells (gastric, mutant p53, highest
expression of MDR1 mRNA) as compared on the basis of
the IC50 values, respectively, representing a significant dif-
ference in the Pgp levels. In addition, the resistance of the
Colo320HSR cells to paclitaxel was reversed by the Pgp
inhibitors including cyclosporine A, verapamil, and
PSC833 (Figure 4B). However, this reversal was not
observed in the SNU-C5 (colon, no MDR1 mRNA) cells as
well as SNU-668. This suggests that Pgp expressed in
colon cancer cells but not gastric cancer cells works func-
tionally and can be inhibited by the Pgp inhibitors.
Comparison of methylation status of MDR1 in gastric and 
colon cancer cells
The methylation status was determined by quantification
PCR-based methylation analysis for a CpG-rich domain to
be approximately 1 Kb containing exon 1 and intron 1
among the MDR1 promoter. To determine the degree of
methylation of the MDR1  gene promoter region, two
primers (MS1 and MS2) containing the Msp I/Hpa II sites
were designed from exon 1 and intron 1, respectively. The
primer pair MC was used as a positive control to deter-
mine the quality of the source genomic DNA. In contrast,
the MN that crosses the Msp I/Hpa II site at the triosephos-
phate isomerase gene promoter region and is never meth-
ylated was used as the negative control. Figure 5B shows
typical quantification PCR-based methylation analysis
images of the SNU-5 (gastric) and HT-29 (colon) cells.
The quantification PCR-based methylation analysis
revealed that any PCR products for the MS1 and MS2 were
not produced from Pst1-digested genomic DNA treated
with  Msp  I (methylation-insensitive enzyme). On the
other hand, PCR products for both MS1 and MS2 in the
SNU-5 cells but a PCR product for the MS1 alone in theBMC Gastroenterology 2008, 8:33 http://www.biomedcentral.com/1471-230X/8/33
Page 5 of 14
(page number not for citation purposes)
HT-29 cells were obtained after Hpa II (methylation-sen-
sitive enzyme) treatment, indicating methylation of CpG
at the MS1 and MS2 sites in the SNU-5 cells and only at
the MS2 site in the HT-29 cells. As summarized in Table 1,
methylation was detected at the MS1 and MS2 sites of the
9 gastric cancer cell lines with the exception of SNU-484
but 2 (SNU-C5 and HCT-116) of the 9 colon cancer cell
lines. On the other hand, the HT-29 cells were methylated
only at the MS2 site. The SNU-C5, HT-29 (colon) and
SNU-16 (gastric) cells not expressing MDR1 mRNA were
methylated. Bisulfite DNA sequencing analysis was per-
formed to confirm the methylation. As show in Table 1,
methylation degree (%) of 10 CpG sites on the expended
MS1 site is completely matched with results obtained by
quantification PCR-based methylation analysis.
Effects of 5-aza-2'-deoxcytidine (5AC) and/or trichostatin 
A (TSA) on the expression of MDR1 mRNA in gastric and 
colon cancer cell lines
The DNA methyltransferase inhibitor 5AC and the his-
tone deacetylase (HDAC) inhibitor TSA have been well
known to relieve epigenetic gene repression [22]. This
study examined the effect of 5AC and/or TSA on MDR1
mRNA expression in the gastric and colon cancer lines. In
10 gastric and 9 colon cancer cells, MDR1 mRNA expres-
sion was determined by RT-PCR after treating them with
MDR1 mRNA expression in gastric cancer cell lines Figure 1
MDR1 mRNA expression in gastric cancer cell lines. The level of MDR1 mRNA expression was determined by RT-PCR, 
and normalized by that of mRNA β-actin, which was used as a control for RNA. The cDNA reverse-transcribed from the 
mRNA was amplified separately with each primer pair for MDR1 and β-actin genes. Aliquots of each PCR reaction mixture 
were separated on 7% polyacrylamide gel. The gel was dried and exposed on X-ray film overnight.
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2.5 μM 5AC for 96 hr and/or 100 ng/ml TSA for 48 hr. An
increase was defined in cases showing more than a 1.5-
fold increase. As shown in Table 1, the 5AC treatment
increased the MDR1 mRNA levels in the SNU-1, -5, -601,
-620, -638 and -719 gastric cancer cell lines, and that in
the HCT-116 colon cancer cell line (Figures 6 and 7).
However, 5AC did not induce MDR1 mRNA expression
even in the SNU-16 and SNU-C5 and HT-29 cells whose
MDR1 gene was methylated. The TSA treatment increased
the MDR1 mRNA levels in the SNU-1, -16, -216, -601, -
638, -668 and -719 gastric cancer cell lines and the SNU-
C1, Colo320HSR, DLD-1, H29 and HCT-116 colon can-
cer cell lines (Figure 6 and 7). 5AC showed high cytotox-
icity alone or in combination with TSA, particularly in the
HT-29 cells. Also, TSA showed highly cytotoxic activity
alone or in combination with 5AC, particularly in the
SNU-620 cells. This study also examined the effects of the
combined treatment of 5AC with TSA, which increased
the MDR1 mRNA levels additively in the SNU-5 and -638
cells but synergistically in the SNU-16, -601, -668, -719
and SNU-C5 cells (Table 1).
These results suggest that MDR1 mRNA expression is dif-
ferentially regulated in gastric and colon cancer cells with
respect to the silencing of MDR1 expression through epi-
genetic mechanisms such as DNA methylation and/or his-
tone deacetylation.
Discussion
In this study, we found that the MDR1 mRNA levels in the
gastric cancer cell lines were significantly lower than those
in the colon cancer cell lines, although there were some
variations. These results are consistent with a report show-
ing that Pgp is strongly expressed on the ileum and colon,
at a level that gradually decreases proximally into the jeju-
num, duodenum and stomach [8]. Since the stomach and
colon play major roles in digestion and absorption,
respectively, it is not surprising that transporters such as
MDR1 mRNA expression in the colon cancer cell lines Figure 2
MDR1 mRNA expression in the colon cancer cell lines. The same methodology reported in Figure 1 was used.
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Pgp were differentially expressed in the two normal tis-
sues. Our finding that the differential expression of MDR1
mRNA in cancer cell lines derived from the stomach and
colon is also consistent with published reports [23-26].
Immunopathological studies revealed that Pgp expression
on human tumors was most commonly detected in colon,
renal, and adrenal carcinomas but rarely in lung and gas-
tric carcinomas and certain germ cell tumors [27].
The three-way connection between DNA methylation,
chromatin structure and gene expression was recently
reviewed [28-30]. An important consequence of CpG
methylation is the local silencing of gene expression,
which can be mediated by the direct interference of meth-
ylation with the binding of various transcription factors.
The major component of silencing of gene expression
appears to be the binding of methyl-CpG-binding protein
2 (MeCp2), which has an affinity for methyl-CpG [31,32].
DNA demethylation by 5AC causes the release of the
MeCp2 from the promoter, which activates transcrip-
tional gene expression [10]. It is known that MeCp2 is
also enriched on the MDR1 promoter and is related to its
silencing [33]. 5AC alters the methylation pattern of the
MDR1 promoter in Pgp-negative cells to resemble that of
Pgp-positive cells and activates the promoter such that
MDR1 mRNA is detectable [34].
In this study, the methylation status was also analyzed in
order to determine if the MDR1 silencing is due to hyper-
methylation of the promoter region. Quantification PCR-
based methylation analysis showed methylation in 9
(90%) out of 10 gastric cancer cell lines but only 3 (33%)
out of 9 colon cancer cells, which were completely
matched with the results obtained by bisulfite DNA
MDR1 mRNA expression in gastric and colon cancer cell lines Figure 3
MDR1 mRNA expression in gastric and colon cancer cell lines. The level of MDR1 mRNA expression was determined 
by real-time RT-PCR, and normalized by that of mRNA β-actin, which was used as a control for RNA. The cDNA reverse-tran-
scribed from the mRNA was amplified separately with each primer pair for MDR1 and β-actin genes.
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sequencing assay. The latter frequency is relatively high
compared with a different study showing MDR1 methyla-
tion in 24% of 275 colorectal cancers [16]. As showed in
Table 1, complete but not partial methylation in the
extended MS1 site was responsible for increased MDR1
mRNA expression by the treatment with 5AC. In addition,
MS1 site derived from exon 1 of MDR1 promoter has
shown to be more important with respect to gene expres-
sion than MS2 site from intron 1 of MDR1 promoter.
The histone-modifying enzymes such as histone acetyl-
transferase (HAT) and HDAC enzymes also modulate
transcription of MDR1 [15]. Therefore, we have investi-
gated how epigenetic mechanisms, such as DNA methyla-
tion and histone deacetylation, are involved in the
differential expression of MDR1 mRNA between gastric
and colon cancer cells using 5AC and/or TSA. The follow-
ing summarizes the results obtained after the 5AC and/or
TSA treatment. Effects of 5AC and/or TSA are defined as
positive when > 1.5-fold is increased after treatment.
1) In gastric cancer cells, 5AC and TSA induced MDR1
mRNA expression at a frequency of 6/10 (60%) and 7/10
(70%), respectively. On the other hand, in colon cancer
cells, 5AC and TSA induced MDR1 mRNA expression at a
frequency of 1/9 (11%) and 5/9 (55%), respectively. This
suggest that DNA methylation is at least partly responsible
for the low level of MDR1 mRNA expression in gastric
cancer cells but is rarely involved in colon cancer cells
whereas HDAC may play important roles in MDR1 mRNA
expression in both cells.
2) 5AC alone had no effect but combined with TSA syner-
gistically increased the MDR1 mRNA expression level in
20% (SNU-16 and -668) of gastric cancer cells but only
the SNU-C5 colon cancer cells. This suggests that the
expression of a methylated MDR1 gene insensitive to 5AC
alone increased with the assistance of TSA. This result is
consistent with a previous report that silencing conferred
by MeCp2 and methylated DNA can be also relieved by
inhibition of HDAC, facilitating the remodelling of chro-
matin and transcriptional activation [35]. Although TSA
alone cannot activate hypermethylted MDR1 [10], it can
lead to upregulation of non-methylated or sparely meth-
ylated promoters [36]. Thus, epigenetic modifications of
DNA and histone have been shown to be responsible for
Comparison of Pgp expression and function in gastric and colon cancer cell lines Figure 4
Comparison of Pgp expression and function in gastric and colon cancer cell lines. (A) Comparative sensitivity of 
Colo320HSR (colon, highest), SNU-668 (gastric, highest) and SNU-C5 (colon, no expression) to paclitaxel; (B) Effects of Pgp 
inhibitors on the sensitivity of Colo320HSR, SNU-668 and SNU-C5 to paclitaxel (IC10 concentration; 50 μM, 0.3 nM and 0.5 
nM, respectively). Sensitivity to paclitaxel was determined using MTT assay in the presence or absence of the Pgp inhibitors 
(cyclosporin A, verapamil and PSC833 of 0.8 μM each). *, P <0.05 versus the control.
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MDR1 gene silencing. However, it is still unclear which
one is first, DNA methylation or histone modifications
[37]. Moreover, combined effect of 5AC with TSA was less
than that of 5AC or TSA alone in gastric (SNU-1) and
colon (SNU-C1, Colo320HSR and DLD-1) cancer cells,
indicating a more complex relation between the methyl-
ated DNA and HDAC.
3) TSA but not 5AC induced MDR1 mRNA expression in
30% (SNU 16, -216 and – 668) of gastric cancer cells and
40% (SNU-C1, COLO32HSR, DLD-1 and HT-29) of
colon cancer cells. These findings suggest that HDAC is
dominant over DNA methylation in cancer cells whose
MDR1  genes are not methylated. However, synergistic
effects of TSA when combined with 5AC showing no effect
in gastric cancer cells (SNU-16 and -668) with unmethyl-
Table 1: Methylation status and the effects of 5AC and/or TSA on MDR1 mRNA expression and in various gastric and colon cancer cell 
lines
DNA methylation assay
Tissue Cell line 5AC Restriction Enzyme Sodium Bisulfite TSA 5AC +TSA
Fold Effect Site Degree (%)1 Fold Effect Fold Effect
Gastric SNU-1 32.6 O MS1 MS2 100 20.7 O +23.6 D
SNU-5 5.8 O MS1 MS2 100 1.03 X 6.8 A
SNU-16 n.d. X MS1 MS2 60 8.4 O 28.9 S
SNU-216 -1.0 X MS1 MS2 50 8.4 O 8.2 N
SNU-484 -1.3 X - - 0 -5.1 X -0.17 -
SNU-601 3.2 O MS1 MS2 100 3.3 O 13.7 S
SNU-620 67.6 O MS1 MS2 100 * X * *
SNU-638 68.9 O MS1 MS2 100 5.7 O 72.9 A
SNU-668 -1.0 X MS1 MS2 80 1.8 O 4.4 S
SNU-719 5.8 O MS1 MS2 100 4.2 O 12.4 S
Colon SNU-C1 -1.96 X n.d. n.d. 0 1.7 O +1.0 D
SNU-C4 1.0 X n.d. n.d. 0 -1 X -1.6 N
SNU-C5 n.d. X MS1 MS2 100 n.d. X 8 S
Colo320HSR 1.4 X n.d. n.d. 0 1.6 O +1.3 D
LoVo -1.9 X n.d. n.d. 0 1.1 X -2 N
DLD-1 1.1 X n.d. n.d. 0 3.5 O +1.1 D
HT-29 * X n.d. MS2 0 ∞ O* *
HCT-8 1.0 X n.d. n.d. 0 1.0 X 1.1 N
HCT-116 1.7 O MS1 MS2 100 1.6 O 1.6 N
1Sequence was analyzed using PCR products containing the extended MS1 site that has been shown to play an important role in MDR1 mRNA 
expression. n.d., not detected; *, highly cytotoxic; ∞, an increase as compared with no MDR1 mRNA expression; D, decreased; A, additive; S, 
synergistic; N, not changedBMC Gastroenterology 2008, 8:33 http://www.biomedcentral.com/1471-230X/8/33
Page 10 of 14
(page number not for citation purposes)
ated MDR1gene are not fully understood. The possibility
of involvement of histone methylation in silencing of
MDR1 expression remains to be determined.
4) The combined treatment of 5AC with TSA increased
MDR1 mRNA expression either additively 20% (SNU-5
and -638) or synergistically 40% (SNU-16, -601, -668 and
-719) in the gastric cancer cells but only synergistically in
the SNU-C5 colon cancer cells. The synergistic effect of
5AC and TSA in gastric cancer cells can be explained on
the basis of a report showing that the methylated gene
binds MeCP2, which in turn recruits HDAC resulting in
the suppression of transcription [32,35].
5) Neither 5AC nor TSA induced MDR1 mRNA expression
even in gastric (SNU-484) and colon (SNU-C4, -C5 and
Lovo) cancer cells even though combination of 5AC and
TSA increased MDR1 mRNA expression in the SNU-C5
cells. This suggests the involvement of other factors in
MDR1 mRNA expression or inappropriate concentrations
and incubation period of each inhibitor.
The quantification PCR-based methylation analysis of gastric and colon cancer cell lines Figure 5
The quantification PCR-based methylation analysis of gastric and colon cancer cell lines. (A) CpG sites and Hpa II/
Msp I sites in the human MDR1 promoter region. Top: The CpG sites are represented by the short vertical bars. The positions 
of exons 1 and 2 are indicated as closed boxes. The position corresponding to these fragments are indicated. Middle: Hpa II/
Msp I recognition sites are represented by short vertical bars. Bottom, PCR primers used in methylation analysis. (B) Repre-
sentative methylation status of the MDR1 promoter region by quantification PCR-based methylation analysis in SNU-5 (gastric) 
and HT-29 (colon). 1: MN, Never-methylated Hpa II/Msp I site at the triosephosphate isomerase gene promoter region (nega-
tive control) (240 bp); 2: MC, the positive control primer pair (240 bp); 3: MS1, Hpa II/Msp I site 1 (121 bp); 4: MS2, Hpa II/Msp 
I site 2 (206 bp).
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One of the aims of this study was to explain why the dif-
ferent 5-FU-based anticancer therapies have been used in
gastric and colorectal cancers using differential MDR1
expression. It has been well known that high levels of
thymidylate synthase activity are responsible for the resist-
ance to 5-FU [38]. However, antimetabolites such as 5-FU
are not substrates for the ATP-dependent efflux transport-
ers such as Pgp expressed on the apical (brush-border)
membrane of intestinal epithelial cells [39-41]. Therefore,
the in vitro and in vivo anticancer efficacy of 5-FU can be
explained not only by the increase in its intracellular accu-
mulation in cancer cells but also by the enhancement of
its bioavailability when administered orally. In gastric
cancer, even anthracyclines (doxorubicin or epirubicin)
and mitomycin C, which are good Pgp substrates, have
been used to treat gastric cancer cells, which are character-
ized by zero or low levels of Pgp, which would make them
sensitive to these anticancer drugs. In colon cancer, a
number of novel anticancer drugs including oxaliplatin
and irinotecan have been used in various combinations
[3]. Platinum compounds such as oxaliplatin, which are
not substrates for Pgp and breast cancer resistance protein
(BCRP), have been used as effective agents against color-
ectal cancer. Even though irinotecan is a BCRP substrate,
it has been shown to be effective in colon cancers with a
significantly lower BCRP expression level than that of the
normal colon [42]. Nevertheless, it is essential that sub-
strate drugs (topotecan, irinotecan, anthracyclines, mito-
mycin C and trimetrexate) for Pgp and/or BCRPS used
clinically in colon cancer be administered in conjunction
with chemosensitizers (VX-710 [43], GF120918 [44,45],
and XR-9576 [46,47]), which can reverse both Pgp and
BCRP.
Activation of MDR1 mRNA expression by 5AC and/or TSA in gastric cancer cells Figure 6
Activation of MDR1 mRNA expression by 5AC and/or TSA in gastric cancer cells. The expression level is reported 
as the ratio of MDR1/β-actin. The total RNA was isolated after treatment with 2.5 μM 5AC for 96 hr and/or 100 ng/ml TSA for 
48 hr. RT-PCR was performed using the same methodology reported in Figure 1.
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Conclusion
The MDR1 mRNA levels in the gastric cancer cell lines
were significantly lower than those in the colon cancer cell
lines, which is at least in part due to differential epigenetic
regulations such as DNA methylation and/or HDAC.
Therefore, MDR1/Pgp plays more important roles in the
transporting function in colon cancer cells than in gastric
cancer cells. These results can provide a better understand-
ing of the efficacy of combined chemotherapy as well as
their oral bioavailability.
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